Duration of Pain Relief
Conditions
Keywords
block duration, analgesia
Brief summary
Effect of dexamethasone on prolonging upper extremity block is well known. But it not known if the effect comes from its local effect on the nerves or from its general analgesic effect. In this study we will compare the systemic effect to its local effect to find out if there is a difference or not.
Interventions
DRUGDexamthsone
DRUGBupivacaine
Sponsors
University of Chicago
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* age 18-75, no contraindication to regional anesthesia,
Exclusion criteria
* opioid user, chronic pain conditions, peripheral neuropathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analgesia Duration | 72 hrs |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Bupivacaine Control
Bupivacaine | 3 |
| Bupivacaine With Dexamethasone Dexamethasone will be mixed with bupivacaine
Dexamthsone
Bupivacaine | 1 |
| Intravenous Dexamethasone Dexamethasone will be given intravenously
Dexamthsone
Bupivacaine | 1 |
| Total | 5 |
Baseline characteristics
| Characteristic | Bupivacaine | Bupivacaine With Dexamethasone | Intravenous Dexamethasone | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 1 Participants | 1 Participants | 5 Participants |
| Region of Enrollment United States | 3 Participants | 1 Participants | 1 Participants | 5 Participants |
| Sex/Gender, Customized Female | 2 Participants | 1 Participants | 1 Participants | 4 Participants |
| Sex/Gender, Customized Male | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 3 | 0 / 1 | 0 / 1 |
| serious Total, serious adverse events | 0 / 3 | 0 / 1 | 0 / 1 |
Outcome results
Primary
Analgesia Duration
Time frame: 72 hrs
Population: study terminated prematurely due to lack of resources and participation- no data collected for Outcome measures and no analysis done